

September 28, 2016

Toray Industries, Inc.  
Japan Tobacco Inc.  
Torii Pharmaceutical Co., Ltd.

**Toray Applies for Japanese Approval of Additional Indication of Pruritus  
Treatment REMITCH® CAPSULES 2.5µg**

Toray Industries, Inc. (head office: Tokyo; President: Akihiro Nikkaku; hereinafter referred to as “Toray”) today announced that it filed for an additional indication of improving pruritus in peritoneal dialysis patients (use only when sufficient efficacy is not obtained with the existing therapies or treatments) (hereinafter referred to as the “new indication”) for REMITCH® CAPSULES 2.5 µg (generic name: nalfurafine hydrochloride; hereinafter referred to as the “Agent”) in Japan on September 28, 2016. Toray has already received the manufacturing and marketing approval for the Agent, which is promoted and distributed by Torii Pharmaceutical Co., Ltd. (head office: Tokyo; President: Shoichiro Takagi) as a pruritus treatment in the country. (Affiliation: Japan Tobacco Inc. [head office: Tokyo, President: Mitsuomi Koizumi])

The Agent is the highly selective kappa opioid receptor agonist invented by Toray and has been distributed in Japan as a treatment of pruritus for hemodialysis patients (approved in 2009) and chronic liver disease patients (approved in 2015) (use only when sufficient efficacy is not obtained with the existing therapies or treatments) (Promotional activities for pruritus in chronic liver disease patients are conducted by Sumitomo Dainippon Pharma Co., Ltd. [head office: Osaka; President: Masayo Tada]).

The three companies hope that gaining approval for the new indication will serve as a new option and significantly contribute to the treatment of pruritus in peritoneal dialysis patients.

###

## **Company Profiles**

Toray Industries, Inc.

Head office: 1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo

President: Akihiro Nikkaku

Capitalization: 147,873 million yen (as of the end of June 2016)

Japan Tobacco Inc.

Head office: 2-1, Toranomom 2-chome, Minato-ku, Tokyo

President: Mitsuomi Koizumi

Capitalization: 100,000 million yen (as of the end of June 2016)

Torii Pharmaceutical Co., Ltd.

Head office: Torii Nihonbashi Building, 4-1, Nihonbashi-Honcho 3-chome, Chuo-ku, Tokyo

President: Shoichiro Takagi

Capitalization: 5,190 million yen (as of the end of June 2016)

## **Media Contacts**

Toray Industries, Inc.

Corporate Communications Department

Tokyo: +81-3-3245-5179

Japan Tobacco Inc.

Media and Investor Relations Division

Tokyo: +81-3-5572-4292

Torii Pharmaceutical Co., Ltd.

Corporate Planning Department

Tokyo: +81-3-3231-6814

###